Stimuli-responsive polyvinylpyrrolidone-NIPPAm-lysine graphene oxide nano-hybrid as an anticancer drug delivery on MCF7 cell line
Source abstract
Abstract
Despite the advances in the development of chemotherapeutic agents, resistance to chemotherapy and adverse side effects are still big challenges against successful cancer treatment. To overcome these problems, one strategy is the application of nanomaterials and drug delivery systems to efficiently deliver the anticancer agents to tumour tissues with minimum toxic effects on healthy organs. In this study a graphene oxide nanohybrid (GO/NHs) was designed and fabricated for the delivery of chemotherapeutic agent fluorouracil (FU) to the breast cancer MCF7 cells. After preparation and characterization of GO/NHs, several biological analysis including haemolysis assay, cytotoxicity assay, cellular uptake, apoptosis assay, and protein expression were performed. The cytotoxic effects of FU, FU loaded GO/NHs (FU-GO/NHs), and blank GO/NHs was determined by MTT assay. The results of MTT assay showed no significant cytotoxicity for blank nano-hybrid on MCF7 cells. Furthermore, FU-GO/NHs were more cytotoxic than free FU. The uptake analysis results showed that developed nanocarrier could completely be internalized into the cells in the first hour. Besides, apoptotic effects and nuclear morphology changes of cells was evaluated by DAPI staining under fluorescent microscopy. Protein expression levels of p53, PARP, cleaved PARP, Bcl-2, and Bax were determined by western blot analysis. Western blot results showed higher levels of p53 and cleaved PARP after treatment with FU-GO/NHs, however, no substantial effect was observed for Bax and Bcl-2 protein concentrations.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Tabriz branch, Islamic Azad University
Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences
Drug Applied Research Center, Tabriz University of Medical Sciences
Universal Scientific Education and Research Network (USERN)
References (28)
Show source-provided references
1. 10.3322/caac.2125410.3322/caac.21254 ↗
2. 10.3322/caac.2134910.3322/caac.21349 ↗
3. 10.1007/s00520-015-2959-310.1007/s00520-015-2959-3 ↗
4. 10.1016/S0140-6736(05)66544-010.1016/S0140-6736(05)66544-0 ↗
5. Sharp III TE, George JC. Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment. Front in Oncol. 2014;4:299.
6. 10.1002/adma.20150220110.1002/adma.201502201 ↗
7. 10.1002/anie.20140951910.1002/anie.201409519 ↗
8. 10.1016/j.jconrel.2014.11.01110.1016/j.jconrel.2014.11.011 ↗
9. 10.1016/j.msec.2016.11.07310.1016/j.msec.2016.11.073 ↗
10. 10.1039/C6PY01365A10.1039/C6PY01365A ↗
11. 10.1007/s11095-018-2404-710.1007/s11095-018-2404-7 ↗
12. 10.1016/j.clay.2017.02.01510.1016/j.clay.2017.02.015 ↗
13. 10.1016/j.carbpol.2018.05.05910.1016/j.carbpol.2018.05.059 ↗
14. 10.1039/C7PY01701D10.1039/C7PY01701D ↗
15. 10.1016/j.addr.2016.05.01510.1016/j.addr.2016.05.015 ↗
16. 10.1080/10408436.2014.100260410.1080/10408436.2014.1002604 ↗
17. 10.1016/j.actbio.2013.08.01610.1016/j.actbio.2013.08.016 ↗
18. 10.1016/j.eurpolymj.2018.02.03610.1016/j.eurpolymj.2018.02.036 ↗
19. 10.1080/10584587.2015.104032810.1080/10584587.2015.1040328 ↗
20. 10.1016/j.jcis.2017.06.00710.1016/j.jcis.2017.06.007 ↗
21. 10.1038/nrd433310.1038/nrd4333 ↗
22. 10.1016/j.actbio.2015.01.01010.1016/j.actbio.2015.01.010 ↗
23. 10.1021/nn900227d10.1021/nn900227d ↗
24. 10.1039/C8NJ01790E10.1039/C8NJ01790E ↗
25. 10.1111/cbdd.1307810.1111/cbdd.13078 ↗
26. 10.1039/C6NJ04107H10.1039/C6NJ04107H ↗
27. Yde CW, Issinger O-G. Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol. 2006;29:1397–1404.
28. 10.1039/C6NJ03332F10.1039/C6NJ03332F ↗